File: '\\swfile\EmailIn\20251208 150425 Attachment IZO_20251208_NR_DebtSettlement.docx'

2

2

Izotropic Announces Debt Settlement

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Nov. 12, 2025, Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a debt settlement agreement (the "Agreement") with a lender (the "Lender") to settle outstanding interest payable pursuant to a promissory note originally issued by the Company.

The Company previously entered into a promissory note dated April 1, 2022, with the Lender in the principal amount of $2,000,000 (the "Promissory Note"). As of the date hereof, the Company owed the Lender $60,000 in accrued interest, representing three (3) months of interest for the period from July to September 2025 (the "Interest").

Pursuant to the Agreement, the Company will settle the Interest through the issuance of 240,000 units (each, a "Unit") at a deemed price of $0.25 per Unit, in full settlement of the Interest. Each Unit will consist of one common share in the capital of the Company (each, a "Share") and one share purchase warrant (each, a "Warrant"), with each Warrant entitling the holder to acquire one additional Share (each, a "Warrant Share") at a price of $0.35 per Warrant Share for a period of five (5) years from the date of issuance.

All securities to be issued in connection with the Interest Settlement will be subject to a statutory hold period of four (4) months and one (1) day, in accordance with applicable securities laws.

Completion of the Interest Settlement remains subject to the approval of the Canadian Securities Exchange.

About Izotropic:

More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR+ at sedarplus.ca.

Contacts:

Robert Thast, Interim Chief Executive Officer

Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1

Email: bthast@izocorp.com

General and Corporate Inquiries

Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3

Email: info@izocorp.com

Cautionary Note Regarding Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of applicable Canadian securities laws. Forward-looking statements are based on the beliefs, expectations, assumptions, and opinions of management as of the date of this news release and include, without limitation, statements regarding the completion of the Interest Settlement and the receipt of required regulatory approvals. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those expressed or implied in such statements. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements.